Order Article Reprints

Corbelli I, Verzina A, Leone De Magistris I, De Vanna G, Eusebi P, Mataluni G, Pisani A, Prudenzano AMP, Trojano M, Delussi M, et al. Sustained Efficacy, Safety and High Adherence Rate of Onabotulinum Toxin Type A in Chronic Migraine Patients: A Multicentric Prospective Real-Life Study. Toxins. 2023; 15(1):34. https://doi.org/10.3390/toxins15010034

Corbelli, Ilenia, Angela Verzina, Ilaria Leone De Magistris, Gioacchino De Vanna, Paolo Eusebi, Giorgia Mataluni, Antonio Pisani, Addolorata Maria Pia Prudenzano, Maria Trojano, Marianna Delussi, and et al. 2023. "Sustained Efficacy, Safety and High Adherence Rate of Onabotulinum Toxin Type A in Chronic Migraine Patients: A Multicentric Prospective Real-Life Study" Toxins 15, no. 1: 34. https://doi.org/10.3390/toxins15010034

Corbelli, I., Verzina, A., Leone De Magistris, I., De Vanna, G., Eusebi, P., Mataluni, G., Pisani, A., Prudenzano, A. M. P., Trojano, M., Delussi, M., De Tommaso, M., Russo, A., Silvestro, M., Tedeschi, G., Calabresi, P., & Sarchielli, P. (2023). Sustained Efficacy, Safety and High Adherence Rate of Onabotulinum Toxin Type A in Chronic Migraine Patients: A Multicentric Prospective Real-Life Study. Toxins, 15(1), 34. https://doi.org/10.3390/toxins15010034